bioMérieux S.A.

ENXTPA:BIM Stock Report

Market Cap: €14.1b

bioMérieux Future Growth

Future criteria checks 3/6

bioMérieux is forecast to grow earnings and revenue by 12.6% and 6.8% per annum respectively. EPS is expected to grow by 12.5% per annum. Return on equity is forecast to be 12.7% in 3 years.

Key information

12.6%

Earnings growth rate

12.47%

EPS growth rate

Medical Equipment earnings growth13.5%
Revenue growth rate6.8%
Future return on equity12.68%
Analyst coverage

Good

Last updated17 May 2025

Recent future growth updates

bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?

Sep 08
bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?

Recent updates

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

May 07
These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

bioMérieux S.A. (EPA:BIM) Not Lagging Market On Growth Or Pricing

Feb 11
bioMérieux S.A. (EPA:BIM) Not Lagging Market On Growth Or Pricing
author-image

FDA Approvals And Expansion Of Installed Base Will Drive Future Success

bioMérieux's strategic plan targets high growth in organic sales and EBIT, with improvements in revenue and net margins by enhancing operational efficiencies.

A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Jan 21
A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Slowing Rates Of Return At bioMérieux (EPA:BIM) Leave Little Room For Excitement

Dec 10
Slowing Rates Of Return At bioMérieux (EPA:BIM) Leave Little Room For Excitement

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Nov 01
Is bioMérieux (EPA:BIM) Using Too Much Debt?

Is There An Opportunity With bioMérieux S.A.'s (EPA:BIM) 31% Undervaluation?

Oct 14
Is There An Opportunity With bioMérieux S.A.'s (EPA:BIM) 31% Undervaluation?

bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing

Sep 26
bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing

bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?

Sep 08
bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?

Return Trends At bioMérieux (EPA:BIM) Aren't Appealing

Aug 03
Return Trends At bioMérieux (EPA:BIM) Aren't Appealing

bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

May 30
bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

Earnings and Revenue Growth Forecasts

ENXTPA:BIM - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20274,9386765961,0898
12/31/20264,58359149694512
12/31/20254,27452748687812
12/31/20243,980432322667N/A
9/30/20243,893422239581N/A
6/30/20243,807411156495N/A
3/31/20243,741384132470N/A
12/31/20233,675358107445N/A
9/30/20233,688372140459N/A
6/30/20233,701386172472N/A
3/31/20233,645419180474N/A
12/31/20223,589452188475N/A
9/30/20223,525502297583N/A
6/30/20223,460552406690N/A
3/31/20223,418577470757N/A
12/31/20213,376601535825N/A
9/30/20213,296555424716N/A
6/30/20213,216509314608N/A
3/31/20213,167457310595N/A
12/31/20203,118404305583N/A
9/30/20202,997355261538N/A
6/30/20202,876305217493N/A
3/31/20202,775289176451N/A
12/31/20192,675273135408N/A
9/30/20192,601268160419N/A
6/30/20192,527263185431N/A
3/31/20192,474260179415N/A
12/31/20182,421257173400N/A
9/30/20182,372264N/A370N/A
6/30/20182,323271N/A340N/A
3/31/20182,306255N/A341N/A
12/31/20172,288238N/A341N/A
9/30/20172,262216N/A340N/A
6/30/20172,237195N/A339N/A
3/31/20172,170187N/A337N/A
12/31/20162,103179N/A336N/A
9/30/20162,068158N/A339N/A
6/30/20162,032137N/A342N/A
3/31/20161,998124N/A326N/A
12/31/20151,965111N/A310N/A
9/30/20151,908127N/AN/AN/A
6/30/20151,851144N/A301N/A
3/31/20151,775140N/A300N/A
12/31/20141,698135N/A298N/A
9/30/20141,656135N/AN/AN/A
6/30/20141,614135N/A246N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIM's forecast earnings growth (12.6% per year) is above the savings rate (1.6%).

Earnings vs Market: BIM's earnings (12.6% per year) are forecast to grow faster than the French market (12% per year).

High Growth Earnings: BIM's earnings are forecast to grow, but not significantly.

Revenue vs Market: BIM's revenue (6.8% per year) is forecast to grow faster than the French market (5.1% per year).

High Growth Revenue: BIM's revenue (6.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BIM's Return on Equity is forecast to be low in 3 years time (12.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/20 01:32
End of Day Share Price 2025/05/20 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

bioMérieux S.A. is covered by 33 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Armelle MoulinAlphaValue
Gaurav JainBarclays
Thomas JonesBerenberg